1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategies for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http://www.goldcopd.org . Accessed 25 May 2015.
2. European Medicines Agency. Daliresp® (roflumilast tablets): EU summary of product characteristics. 2011. http://www.ema.europa.eu . Accessed 29 Jul 2015.
3. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163(1):53–67.
4. Giembycz MA, Maurice DH. Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol. 2014;16(Suppl C):89–107.
5. Takeda. Daliresp® (roflumilast tablets): US prescribing information. 2014. http://pi.actavis.com . Accessed 29 Jul 2015.